Menu
Annual · values202520242023
Gross Margin
Operating Margin32.15%
EBITDA Margin32.54%
Net Margin45.44%
Current Ratio27.5020.6923.29
Quick Ratio27.5020.6923.29
Debt / Equity
ROE-22.98%-21.34%-33.44%
ROA-21.68%-19.85%17.43%
Asset Turnover0.000.38
Book Value / Share9.4210.23-20.01

Continua Therapeutics Inc. is a biotechnology company focused on the development and commercialization of innovative therapeutic solutions. Its primary function lies in advancing novel drug candidates aimed at addressing unmet medical needs within the healthcare sector. The company emphasizes research and development, with a focus on diseases that currently lack effective treatment options, potentially impacting various medical fields such as oncology, neurology, and autoimmune disorders. Continua Therapeutics Inc. is significant in the market due to its commitment to pioneering next-generation pharmaceuticals that could redefine standard treatment protocols. Through strategic collaborations and a robust pipeline of research projects, the company plays a critical role in the biotech industry, pushing the boundaries of medical science.